IDEXX Laboratories lifts FY26 revenue guidance after strong Q3 results. Read here for a detailed investment analysis of IDXX stock.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
IDEXX Laboratories stock barely moved after its Q3 2026 report, edging up about 0.1% to around US$672. For a business trading on a rich P/E multiple of roughly 45x, that muted reaction might look like a shrug. It is not; the real story sits in the earnings power that is being used to justify that valuation. Quarterly revenue reached about US$1.2b and basic earnings per share came in just over US$4, underpinned by a trailing net profit margin of 25.4%. If you focus only on today’s tiny price...
IDEXX Laboratories' (IDXX) latest results demonstrated its ability to sustain strong performance des
Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.
The veterinary diagnostics company saw sales and profit grow more than Wall Street expected.
IDEXX stock surged 21% after a Q3 earnings beat and higher 2026 guidance.
Detailed price information for Nvidia Corp (NVDA-Q) from The Globe and Mail including charting and trades.
Idexx Laboratories reported strong growth in veterinary diagnostics, offsetting sluggish industry demand.
Motley Fool Press Release.
Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.
Idexx Laboratories outperformed a shaky macro on Monday, beating third-quarter forecasts. Idexx stock surged.
Investing.com -- IDEXX Laboratories Inc. (NASDAQ:IDXX) reported third quarter results that exceeded analyst expectations and raised its full-year outlook on Monday.
This is the newest page. Registered accounts read further back.